ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2186

The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies

Savino Sciascia1, Beverely J Hunt2, Eva Talavera-Garcia3, Gloria Lliso3, Munther Khamashta3 and Mª Jose Cuadrado4, 1Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 2Thrombosis & Haemostasis, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, 3Louise Coote Lupus Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, 4Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Antiphospholipid antibodies, antiphospholipid syndrome, hydroxychloroquine and pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Antiphospholipid Syndrome: Clinical

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all maternal, foetal and neonatal complications of APS. This observational, retrospective, single-centre cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibody(aPL) treated with hydroxychloroquine (HCQ) in addition to conventional treatment during pregnancy.

Methods: One-hundred and seventy pregnancies in 96 women with persistent aPL were analysed:51 pregnancies occurred in 31 women treated with HCQ for at least six months prior to pregnancy and continued throughout gestation(group A);119 pregnancies occurred in 65 women with aPL not treated with HCQ were included as controls (group B).

Results: HCQ-treatment was associated with a higher rate of live births (67%groupA vs. 57% group B,p=0.05)and a lower prevalence of aPL-related pregnancy morbidity (47% group A vs. 63% B,p=0.004).The association of HCQ with the absence of any complication in pregnancy was confirmed after multivariate analysis (OR 2.2;95%CI 1.2-136;p=0.04). Fetal losses>10thweeks of gestation(2% vs. 11%,p=0.05)and placenta mediated complications (2% vs 11%,p=0.05)were less frequent in group A than B.Pregnancy duration was longer in group A than B(27.6 [6-40] vs. 21.5[6-40] weeks,p=0.03).There was a higher rate of spontaneous vaginal labour in HCQ-treated women compared to group B(37.3% vs. 14.3%,p=0.01). 

Conclusion: Despite the heterogeneity in the two groups in terms of SLE prevalence and previous pregnancy history, our results support the concept that women with aPL may benefit from treatment with HCQ during pregnancy to improve pregnancy outcome.The addition of HCQ to conventional treatment is worthy of further assessment.


Disclosure: S. Sciascia, None; B. J. Hunt, None; E. Talavera-Garcia, None; G. Lliso, None; M. Khamashta, None; M. J. Cuadrado, None.

To cite this abstract in AMA style:

Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta M, Cuadrado MJ. The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-role-of-hydroxychloroquine-treatment-on-pregnancy-outcome-in-women-with-antiphospholipid-antibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-hydroxychloroquine-treatment-on-pregnancy-outcome-in-women-with-antiphospholipid-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology